News

Alchemia Oncology Pty Limited has a robust collection of clinical and pre-clinical oncology assets, which include the HyACT Drug Delivery Platform, a portfolio of targeted therapeutics which are

New companies Lupin and Strides Arcolab recently signed agreements to produce dolutegravir (DTG), a promising new HIV medicine the MPP licensed from ViiV Healthcare two months after its

The fact that R-Japan received the license of cell processing facility through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 two months after

Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the

RHB-104 is an antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. Currently, RHB-104 is undergoing a first Phase III study for Crohn’s

Jointly developed with Nexgen Pharma, Tuxarin ER will be the first product to provide long lasting cough suppression with a safer opiate that is less prone to respiratory

The NIH grant of $299,585 is for the first year of a two-year project period beginning this July. The grant will be used to support the preclinical testing

The tablet combines Gilead’s emtricitabine 200mg and tenofovir alafenamide (TAF) 25mg with Janssen Sciences Ireland’s rilpivirine 25mg (R/F/TAF). The company said that the data submitted in the NDA

DE-122 is the ophthalmic formulation of Santen’s partner Tracon Pharmaceuticals’ anti-endoglin antibody, TRC105. In March last year, Santen licensed the global rights for the development of TRC105 in